PROTECTIVE EFFECT OF DEXMEDETOMIDINE
https://doi.org/2078-5658-2018-15-2-55-61
Abstract
Currently, the issue of organ protection is being actively studied. According to results of a big number of studies conducted all over the world, dexmedetomidine, the agonist of α2-adrenoreceptors, possesses certain protective properties. Further multi-center randomized studies are needed in order to prove that this drug can be used to reduce the number of peri-operative complications and the risk of organ dysfunction, and to improve outcomes of surgical treatment in patients with cardiac and non-cardiac operations.
About the Authors
O. N. Ulitkinа
Moscow Regional Research Clinical Institute named after M. F. Vladimirsky
Russian Federation
Russian Federation
Olga N. Ulitkina – Researcher of Intensive Care Department
61/2, Schepkina St., Moscow, 129110
O. A. Grebenchikov
Moscow Regional Research Clinical Institute named after M. F. Vladimirsky
Russian Federation
Russian Federation
Oleg A. Grebenchikov – Doctor of Medical Sciences, Senior Researcher of Intensive Care Department
61/2, Schepkina St., Moscow, 129110
Yu. V. Skripkin
Moscow Regional Research Clinical Institute named after M. F. Vladimirsky
Russian Federation
Russian Federation
Yury V. Skripkin – Candidate of Medical Sciences, Head of Anesthesiology and Intensive Care Department
61/2, Schepkina St., Moscow, 129110
F. F. Bershаdskiy
Moscow Regional Research Clinical Institute named after M. F. Vladimirsky
Russian Federation
Russian Federation
Fedor F. Bershadskiy – Researcher of Intensive Care Department
61/2, Schepkina St., Moscow, 129110
References
1. State Register of Medications. http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=a3abcbd7-cda0-4b66–9e38-38677da64930&t= (In Russ.)
2. Kassil V.L., Vyzhigina M.А., Eremenko А.А. et al. Ventilyatsiya legkikh v anesteziologii i reanimatologii. [Pulmonary ventilation in anesthesiology and critical care medicine]. Moscow, GEOTAR-Media Publ., 2016, pp. 319-320.
3. Kozlov I.А., Klypa T.V., Аntonov I.O. Dexmedetomidine as a cardiac protector in cardiac surgery (review). Obschaya Reanimatologiya, 2017, vol. 13, no. 4, pp. 46-63. (In Russ.)
4. Ammar A., Mahmoud K., Kasemy Z. et al. Cardiac and renal protective effects of dexmedetomidine in cardiac surgeries: A randomized controlled trial. Saudi J. Anaesthesia, 2016, vol. 10, no. 4, pp. 395-401.
5. Biccard B.M., Goga S., de Beurs J. Dexmedetomidine and cardiac protection for non-cardiac surgery: a meta-analysis of randomized controlled trials. Anaesthesia, 2008, vol. 63, no. 1, pp. 4-14.
6. Carrasco G., Baeza N., Cabre L. et al. Dexmedetomidine for the treatment of hyperactive delirium refractory to haloperidol in nonintubated icu patients: a nonrandomized controlled trial. Crit. Care Med., 2016, vol. 44, no. 7, pp. 1295-1306.
7. Chen K., Lu Z., Xin Y. et al. Alpha-2 agonists for long-term sedation during mechanical ventilation in critically ill patients (Review). Cochrane Database Syst. Rev., 2015, vol. 6, no. 1, CD010269.
8. Chen S., Hua F., Lu J. et al. Effect of dexmedetomidine on myocardial ischemia-reperfusion injury. Int. J. Clin. Exp. Med., 2015, vol. 8, no. 11, pp. 21166-21172.
9. Cheng H., Li Z., Young N. et al. The effect of dexmedetomidine on outcomes of cardiac surgery in elderly patients. J. Cardiothorac. Vasc. Anesth., 2016, vol. 30, no. 6, pp. 1502-1508.
10. Djaiani G., Silverton N., Fedorko L. et al. Dexmedetomidine versus propofol sedation reduces delirium after cardiac surgery: A randomized controlled trial. Anesthesiology, 2016, vol. 124, no. 2, pp. 362-368.
11. Ji F., Li Z., Young J.N. et al. Post-bypass dexmedetomidine use and postoperative acute kidney injury in patients undergoing cardiac surgery with cardiopulmonary bypass. PLoS. One, 2013, vol. 8, no. 10, pp. e77446.
12. Geng J., Qian J., Cheng H. et al. The influence of perioperative dexmedetomidine on patients undergoing cardiac surgery: a meta-analysis. PLoS. One, 2016, vol. 11, no. 4, pp. e0152829.
13. Hartrick C.T., Kovan J.P., Shapiro S. The numeric rating scale for clinical pain measurement: a ratio measure?. Pain Pract., 2003, vol. 3, no. 4, pp. 310-316.
14. Hongo M., Fujisawa S., Adachi T. et al. Age-related effects of dexmedetomidine on myocardial contraction and coronary circulation in isolated guinea pig hearts. J. Pharmacol. Sci., 2016, vol. 131, no. 2, pp. 118-125.
15. Jakob S.M., Ruokonen E., Grounds R.M. et al. Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials. JAMA, 2012, vol. 307, no. 11, pp. 1151-1160.
16. Jessen Lundorf L., Korvenius Nedergaard H. et al.https://www.ncbi.nlm.nih.gov/pubmed/?term=M%C3%B8ller%20AM%5BAuthor%5D&cauthor=true&cauthor_uid=26889627 Perioperative dexmedetomidine for acute pain after abdominal surgery in adults. Cochrane Database Syst Rev., 2016, vol. 18, no. 2, CD010358.
17. Ji F., Li Z., Nguyen H. et al. Perioperative dexmedetomidine improves outcomes of cardiac surgery. Circulation, 2013, vol. 127, no. 15, pp. 1576-1584.
18. Jianjun R., Huijun Zh., Lining H. et al. Protective effect of dexmedetomidine in coronary artery bypass grafting surgery. Exp. Ther Med., 2013, vol. 6, no. 2, pp. 497-502.
19. Jin S., Zhou X. Influence of dexmedetomidine on cardiac complications in non-cardiac surgery: a meta-analysis of randomized trials. Int. J. Clin. Pharm., 2017, vol. 39, no. 4, pp. 629-640.
20. Jin S.C., Jae-Kwang S., Sara S. et al. Perioperative dexmedetomidine reduces the incidence and severity of acute kidney injury following valvular heart surgery. Kidney Int., 2016, vol. 89, pp. 693-700.
21. Kundra T.S., Nagaraja P.S., Singh N.G. et al. Effect of dexmedetomidine on diseased coronary vessel diameter and myocardial protection in percutaneous coronary interventional patients. Ann. Card. Anaesth., 2016, vol. 19, no. 3, pp. 394–398.
22. LinnD.D.https://www.ncbi.nlm.nih.gov/pubmed/?term=Loeser%20KC%5BAuthor%5D&cauthor=true&cauthor_uid=26400008 Dexmedetomidine for alcohol withdrawal syndrome. Ann. Pharmacother., 2015, vol. 49, no. 12, pp. 1336-1342.
23. Liu X., Xie G., Zhang K. et al. Dexmedetomidine vs propofol sedation reduces delirium in patients after cardiac surgery: A meta-analysis with trial sequential analysis of randomized controlled trials. J. Crit. Care, 2017, vol. 38, pp. 190-196.
24. Pandharipande P.P., Sanders R.D., Girard T D. et al. Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori–designed analysis of the MENDS randomized controlled trial. Crit. Care, 2010, vol. 14, no. 2, pp. R38.
25. Pratik P., Brenda T., Daniel L.H. et al. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patientsthe mends randomized controlled trial. JAMA, 2007, vol. 298, no. 22, pp. 2644-2653.
26. Richard R.R., Yahya S., Bokesch P.M. et al. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA, 2009, vol. 301, no. 5, pp. 489-499.
27. Rui S., Hong-Tao T. Dexmedetomidine as a promising prevention strategy for cardiac surgery-associated acute kidney injury: a meta-analysis. Crit. Care, 2017, vol. 21, pp. 198.
28. Schnabel A., Meyer-Friesem C.H., Reichl S.U. et al. Is intraoperative dexmedetomidine a new option for postoperative pain treatment? A meta-analysis of randomized controlled trials. Pain, 2013, vol. 154, no. 7, pp. 1140-1149.
29. Shen J., Sun Y., Han D. et al. Effects of dexmedetomidine on perioperative cardiac adverse events in elderly patients with coronary heart disease. J. Issn., 2017, vol. 42, no. 5, pp. 553-557.
30. Shin H.J., Koo B.W., Bang S.U. et al. Intraoperative dexmedetomidine sedation reduces the postoperative agitated behaviour in elderly patients undergoing orthopaedic surgery compared to the propofol sedation: a retrospective analysis of 855 patients. Minerva Anestesiol., 2017, vol. 83, no. 10, pp. 1042-1050.
31. Sun Y., Jiang C., Jiang J. et al. Dexmedetomidine protects mice against myocardium ischaemic/reperfusion injury by activating an AMPK/PI3K/Akt/eNOS pathway. Clin. Exp. Pharmacol. Physiol., 2017, vol. 44, no. 9, pp. 946-953.
32. Tang C., Xia Z. Dexmedetomidine in perioperative acute pain management: a non-opioid adjuvant analgesic. J. Pain Res., 2017, vol. 10, pp. 1899-1904.
33. Tosun Z., Baktir M., Kahraman H.C. et al. Does dexmedetomidine provide cardioprotection in coronary artery bypass grafting with cardiopulmonary bypass? A pilot study. J. Cardiothorac. Vasc. Anesth., 2013, vol. 27, no. 4, pp. 710-715.
34. Uğur K., Cimen G.O., Bekir U.E. et al. The Effects of dexmedetomidine on secondary acute lung and kidney injuries in the rat model of intra-abdominal sepsis. Sci. World J., 2013, Article ID 292687.
35. Wong A., Smithburger P.L., Kane-Gill S.L. Review of adjunctive dexmedetomidine in the management of severe acute alcohol withdrawal syndrome. Drug. Alcohol Abuse, 2015, vol. 41, no. 5, pp. 382-391.
36. Woods A.D., Giometti R., Weeks S.M. The use of dexmedetomidine as an adjuvant to benzodiazepine-based therapy to decrease the severity of delirium in alcohol withdrawal in adult intensive care unit patients: a systematic review. JBI Database System Rev Implement Rep., 2015, vol. 13, no. 1, pp. 224-252.
37. Wu J., Li S.T. Dexmedetomidine may produce extra protective effects on sepsis-induced diaphragm injury. Chinese Med. J. 2015, vol. 128, no. 10, pp. 1407-1411.
38. Xian S., Zhao-Ting M., Xin-Hai W. et al. Dexmedetomidine for prevention of delirium in elderly patients after non-cardiac surgery: a randomised, double-blind, placebo-controlled trial. Lancet, vol. 388, no. 10054, pp. 1893-1902.
39. Xu L., Hu Z., Shen J. et al. https://www.ncbi.nlm.nih.gov/pubmed/?term=McQuillan%20PM%5BAuthor%5D&cauthor=true&cauthor_uid=25132247 Does dexmedetomidine have a cardiac protective effect during non-cardiac surgery? A randomised controlled trial. CEPP, 2014, vol. 41, no. 11, pp. 879-883.
40. Xue F., Zhang W., Chu H.C. Assessing perioperative dexmedetomidine reduces the incidence and severity of acute kidney injury following valvular heart surgery. Kidney Int., 2016, vol. 89, no. 5, pp. 1164.
41. Yang Y.F., Peng K., Liu H. et al. Clin Dexmedetomidine preconditioning for myocardial protection in ischaemia-reperfusion injury in rats by downregulation of the high mobility group box 1-toll-like receptor 4-nuclear factor κB signalling pathway. Exp. Pharmacol. Physiol., 2017, vol. 44, no. 3, pp. 353-361.
42. Yoshikawa Y., Hirata N., Kawaguchi R. et al. Dexmedetomidine maintains its direct cardioprotective effect against ischemia/reperfusion injury in hypertensive hypertrophied myocardium. Anesth. Analg., 2017, vol. 126, no. 2, pp. 443-452.
43. Zhai M., Kang F., Han M. et al. The effect of dexmedetomidine on renal function in patients undergoing cardiac valve replacement under cardiopulmonary bypass: A double-blind randomized controlled trial. J. Clin. Anesth., 2017, vol. 40, pp. 33-38.
44. Zhang J., Wang Z., Wang Y. et al. The effect of dexmedetomidine on inflammatory response of septic rats. BMC Anesthesiology, 2015, vol. 15, pp. 68.
45. Zhang J.J., Peng K., Zhang J. et al. Dexmedetomidine preconditioning may attenuate myocardial ischemia/reperfusion injury by down-regulating the HMGB1-TLR4-MyD88-NF-кB signaling pathway. PLoS. One, 2017, vol. 12, no. 2, pp. 1-15.
46. Zheng G., Li M., Yu-Lin Z. et al. Myocardial protective effects of dexmedetomidine in patients undergoing cardiac surgery: A meta-analysis and systematic review. Exp. Ther. Med., 2017, vol. 13, no. 5, pp. 2355-2361.
47. Zhou S.Z., Li Z.M., Liu X.R. et al. Bidirectional regulatory effects of dexmedetomidine on porcine coronary tone in vitro. Med., Sci., Monit. 2017, vol. 3, no. 23, pp. 1621-1626.
Review
For citations:
Ulitkinа O.N., Grebenchikov O.A., Skripkin Yu.V., Bershаdskiy F.F. PROTECTIVE EFFECT OF DEXMEDETOMIDINE. Messenger of ANESTHESIOLOGY AND RESUSCITATION. 2018;15(1):55-61. (In Russ.) https://doi.org/2078-5658-2018-15-2-55-61
Email this article 